Prognostic value of p53, glutathione S-transferase π, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer

Hideaki Shiga, Elizabeth I. Heath, Audrey A. Rasmussen, Bruce Trock, Patrick G. Johnston, Arlene A. Forastiere, Miles Langmacher, Alfred Baylor, Michele Lee, Kevin J. Cullen

Research output: Contribution to journalArticle

Abstract

Neoadjuvant cisplatin-based chemotherapy has been widely used in the last decade for organ preservation or unresectable disease in advanced stage head and neck cancer. We examined the expression of a series of tumor markers that have been associated with chemotherapy resistance in pretreatment biopsies from 68 patients who received cisplatin-based neoadjuvant chemotherapy at either of two institutions. Patients received either cisplatin/5-fluorouracil (n = 49) or cisplatin/paclitaxel (n = 19). Expression of p53, glutathione S-transferase-π (GSTπ), thymidylate synthase (TS), c-erbB2, and multidrug resistance-associated protein was examined by immunohistochemistry. Expression of glutathione synthetase mRNA was measured by in situ hybridization. The overall response rate for cisplatin-based neoadjuvant treatment was 79%. The expression of several of the tumor markers was associated with resistance to neoadjuvant treatment, but none reached statistical significance. Overall survival (OS) was strongly correlated with the absence of p53 expression. The OS at 3 years was 81% in the p53-negative group, whereas it was 30% in the p53-positive group for patients treated with neoadjuvant chemotherapy (P <0.0001). Expression of GSTπ and TS was also significantly correlated with decreased OS after neoadjuvant treatment. At 3 years, the OS rate was 82% in the low GSTπ score group, compared to 46% in the high GSTπ score group (P = 0.0018). In the TS-negative group, the 3-year OS rate was 71% compared with 40% in the TS-positive group (P = 0.0071). We conclude that p53, GSTπ, and TS may be clinically important predictors of survival in patients receiving neoadjuvant chemotherapy for head and neck cancer.

Original languageEnglish (US)
Pages (from-to)4097-4104
Number of pages8
JournalClinical Cancer Research
Volume5
Issue number12
Publication statusPublished - Dec 1999

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this